Dalfampridine Treatment for Nonarteritic Anterior Ischemic Optic Neuropathy (NAION)
Phase of Trial: Phase IV
Latest Information Update: 01 Feb 2016
Price : $35 *
At a glance
- Drugs Fampridine (Primary)
- Indications Optic nerve disorders
- Focus Therapeutic Use
- 22 Jan 2016 Status changed from active, no longer recruiting to completed, as reported by ClinicalTrials.gov.
- 05 Oct 2015 Planned End Date changed from 1 Jul 2015 to 1 Jan 2016 according to ClinicalTrials.gov record.
- 05 Oct 2015 Planned primary completion date changed from 1 Aug 2014 to 1 Jan 2016, according to ClinicalTrials.gov record.